Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Don't want ads? Click here
Sponsored Content
Don't want ads? Click here

Pin to quick picksIQ-AI Share News (IQAI)

  • There is currently no data for IQAI

Watchlists are a member only feature

Login to your account

Timelines are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Impellam's first quarter beats pre-virus levels

Thu, 28th Apr 2022 19:25

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Impellam Group PLC - Luton, England-based recruiter - For the first quarter ended April 1, revenue grows 17% year-on-year to GBP612.7 million, and is also 12% above pre-pandemic levels, leading to earnings before interest, tax, depreciation and amortisation rising 68% to GBP10.1 million from a year prior, and 60% above pre-pandemic levels.

----------

Resolute Mining Ltd - Perth-based gold miner in Africa - For the three months ended March 31, gold poured rises 2% at 81,770 ounces from 79,816 ounces the same period a year before, leading to a 17% increase in gold sales to 88,773 ounces from 75,636 ounces, at an average realised price of USD1,876 per ounce from USD1,749. The improved gold production is from better performances from the Syama Oxide operation in Mali as well as Mako in Senegal.

----------

Aptitude Software Group PLC - London-based finance transformation and automation software - For the year to date, continues to make good operational progress, with new business across its product suite in all regions throughout the first months of the year, including a multi-year eSuite contract win with a global broadcaster, leading to confidence that Aptitude will meet management expectations in performance for 2022.

----------

Libertine Holdings PLC - Sheffield, England-based technology for power generation from renewable fuels - For the year ended March 31, the company delivers GBP3 million in commercial and grant income contract milestones, and has completed the internal combustion systems design and manufacture for the MAHLE Powertrain, which is ready for planned combustion testing from the first quarter of its current financial year. As at March 31, has GBP6.7 million in cash reserves.

----------

C4X Discovery Holdings PLC - Manchester-based developer of drug discoveries - For the six months ended January 31, pretax loss widens to GBP5.5 million from GBP4.5 million the same period a year before, on higher R&D and administrative expenses, while generating GBP66,000 in revenue.

----------

PPHE Hotel Group Ltd - Amsterdam-based hotel owner and operator - For the first quarter ended March 31, total revenue rises sharply to GBP32.0 million from GBP5.3 million the same period a year before, as demand for international travel and hotels grow. However, the figure remains 49% below pre-virus levels, which stands at GBP62.5 million for the three months ended March 31, 2019. Revenue per available room rises to GBP124.1 from GBP72.9 a year prior, as occupancy climbs to 34.2% from 7.1%. Looking ahead, the momentum achieved by PPHE in the first quarter has continued into the second quarter.

----------

Merit Group PLC - business intelligence, media and technology resourcing - For the year ending March 31, adjusted earnings before interest, tax, depreciation and amortisation rises to GBP2.8 million, ahead of market expectations of GBP2.0 million, as revenue increases 10% year-on-year. "The group's recovery and improved financial performance will allow us to concentrate on our strategic goal of building a strong growth company focused on technology enabled business intelligence," says Chief Executive Officer David Beck.

----------

Nexus Infrastructure PLC - Essex, England-based infrastructure services provider - For the six months ended March 31, revenue is expected to grow 25% to GBP80 million from GBP63.9 million, as the total order book as at March 31 stands at GBP306.8 million, a 1.7% rise from GBP301.6 million. Revenue growth is fostered by strong performances from TriConnex and sharp growth from eSmart Networks.

----------

Smoove PLC - Oxfordshire, England-based online platforms for conveyancing and financial intermediary markets - For the year ended March 31, revenue rises 12% to GBP19 million from GBP17 million the year before, as conveyancing completions in the period grows 10% to 37,009, while instructions rise 22% to 67,156. Revenue growth is driven by strong growth in the broker channel and increased demand through a bounce back from Covid-19. Looking ahead, the company continues to see strong trading demand for its flagship eConveyancer brand.

----------

Vianet Group PLC - Stockton-on-Tees, England provider of retail sales and volume monitoring systems - Through a strong recovery in the second half, for the year ended March 31, revenue is expected to to rise 55% to GBP13.0 million from GBP8.4 million the prior year, on new contract wins and device sales. As a result, operating profit is set to be GBP2.2 million, swinging from a loss of GBP700,000.

----------

Kerry Group PLC - Tralee, Ireland-based nutrition products - For the three months ended arch 31, group volumes grow 5.6%, and 6.3% on a like-for-like basis, with growth in Taste & Nutrition and Dairy Ireland. Group revenue grows 8.1% year-on-year, and for 2022 as a whole, expects to achieve adjusted earnings per share rise between 5% and 9% on a constant currency basis.

----------

Mkango Resources Ltd - Vancouver-based explorer for rare earth elements - For 2021, pretax loss widens to USD9.7 million from USD4.1 million the year before, on a sharp rise in administrative costs and mineral project expenditures. Looking ahead, the feasibility study for Songwe is expected to be completed in the second quarter of 2022, while studies for the Pulawy rare earth separation plant in Poland is underway.

----------

Glenveagh Properties PLC - Dublin-based housebuilder - For 2022 to date, company has a total order book of 2,160 units across Suburban and Urban segments, and is on-track to deliver 1,400 Suburban homes in 2022 with 80% sold, signed or received. Looking ahead, the company intends to launch a further EUR75 million buyback programme. "The growth in the Suburban segment, allied with the Partnership's business which is set to materially deliver from 2024, means the group expects to see continued growth in 2024 and beyond," the company states.

----------

IQ-AI Ltd - Jersey-based medical services firm - For 2021, pretax loss narrows to GBP501,058 from GBP717,534 the year before, as revenue more than doubles to a record figure of GBP521,069 from GBP255,314, through the securing of several new patients, and the achievement of new product development milestones.

----------

Creo Medical Group PLC - Chepstow, Wales-based medical device company - For 2021, expects revenue to be at least GBP25 million, more than doubling from GBP9.4 million the year before. This momentum carries on into the first quarter of 2022, with revenue being strong and supported by the reopening of markets post Covid-19 and the resultant backlog of demand for elective procedures and adoption of Creo Speedboat Inject device.

----------

Aseana Properties Ltd - property developer in Malaysia and Vietnam - For the 2021, pretax loss narrows to USD4.8 million from USD9.1 million loss in 2020. Says loss was largely due to the finance cost incurred in relation to RuMa Hotel & Residences and the Sandakan hotel asset and the Harbour Mall in Sandakan, in the Malaysian state of Sabah.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
2 May 2025 13:28

IN BRIEF: IQ-AI applies for breakthrough therapy designation for GaM

IQ-AI Ltd - London-based medical services company - Says subsidiary Imaging Biometrics LLC has applied for breakthrough therapy designation from the US Food & Drug Administration for its oral gallium maltolate therapy. Its phase 1 trial is evaluating the therapy as a potential treatment for adult patients with recurrent or refractory glioblastoma IDH-wildtype, with preliminary findings suggesting an overall survival of 34.1 months from initial diagnosis. This significantly exceeds the median survival of 14 to 15 months reported for patients undergoing standard treatment, though IQ-AI notes that caution is appropriate when considering the results due to the size of the trial population. The FDA is required to respond to IQ-AI's application within 60 days.

Read more
3 Feb 2025 19:22

IN BRIEF: IQ-AI amends distribution deal with Blackford Analysis

IQ-AI Ltd - London-based medical services company - Amends existing distribution agreement with artificial intelligence platform provider Blackford Analysis Ltd. The amendment adds IB Nimble, IB ASL, IB FTB, and IB FTB Express to the agreement, allowing Blackford to also sell these products to their global client base. Acquired by Bayer in early 2023, Blackford operates in the healthcare AI platform and solutions sphere.

Read more
22 Jan 2025 17:10

IN BRIEF: IQ-AI to take GaM to phase II study, flags AI capabilities

IQ-AI Ltd - London-based medical services company - Provides operations update focusing on artificial intelligence. Explains radiology leads the way in Food & Drug Administration approvals for AI-enabled products as the FDA has increased efforts to keep pace with the advancements in AI technology. The company believes its subsidiary, Imaging Biometrics LLC, is in a unique position to lead this transformation for neuro-oncology in 2025 and beyond. Points to the imminent release of the new version of IB Clinic; its FDA-cleared suite of quantitative imaging solutions will include the incorporation of an AI model, which will greatly improve diagnostic accuracy and speed. In addition, notes the first half of 2025 should mark the next release of IB Nimble with the functionality to view IB's AI-generated images and other images within the mobile app. Also, in 2025 we anticipate releasing a new product leveraging arterial spin labelling.

Read more
14 Oct 2024 10:05

IN BRIEF: Braveheart buys 30% stake in IQ-AI from Braveheart CEO Brown

IQ-AI Ltd - parent of Wisconsin-based Imaging Biometrics LLC, which provides quantitative imaging platforms and therapeutics for the diagnosis and treatment of patients - AIM-listed technology investor Braveheart Investment Group PLC buys a nearly 30% stake in IQ-AI from Braveheart Chief Executive Officer Trevor Brown. Braveheart buys 45.8 million IQ-AI shares from Brown at 1.1 pence per share, worth GBP503,372, and another 19.7 million shares owned by Brown's children at the same price, worth GBP216,203. The two purchases give Braveheart a 29.5% stake in IQ-AI. Braveheart on Friday says the related-party transaction is approved by its independent shareholders because the IQ-AI business fits Braveheart's investment strategy and the purchase is at "an attractive entry price".

Read more
16 Aug 2024 20:40

TRADING UPDATES: NetScientific loss narrows; Vinanz ups Bitcoin fleet

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and Wednesday and not separately reported by Alliance News:

Read more
25 Jun 2024 11:56

IN BRIEF: IQ-AI subsidiary opens expanded access programme

IQ-AI Ltd - London-based medical services company - US-based subsidiary Imaging Biometrics LLC says that US Food & Drug Administration has approved an expanded access programme for oral gallium maltolate. This EAP will run in parallel with the current phase 1 clinical trial being conducted at the Medical College of Wisconsin. Explains that "As the phase 1 trial concludes this fall and while the data is being compiled, eligible patients in the US will have the option of participating in the EAP."

Read more
14 Jun 2024 14:32

IQ-AI team begins defining phase 2 protocol for oral gallium maltolate

(Alliance News) - IQ-AI Ltd on Friday said the clinical team has started a phase 2 protocol for its oncology-focused drug oral gallium maltolate, which could be a therapeutic agent for cancer.

Read more
23 May 2024 21:08

TRADING UPDATES: Celadon ships to US; Oxford BioDynamics-Goodbody pact

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
20 May 2024 11:16

IQ-AI subsidiary gets second FDA rare paediatric disease designation

(Alliance News) - IQ-AI Ltd on Monday said its subsidiary, Imaging Biometrics LLC, received a second rare paediatric disease designation by the US Food & Drug Administration for its IB-003 lead drug candidate oral gallium maltolate.

Read more
17 May 2024 17:39

TRADING UPDATES: Ingenta trades in line; Triple Point Social NAV up

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
10 May 2024 15:14

IQ-AI subsidiary gets rare paediatric disease designation FDA

(Alliance News) - IQ-AI Ltd on Friday said its subsidiary, Imaging Biometrics LLC, has been granted rare paediatric disease designation by the US Food & Drug Administration for its lead drug candidate, IB-003, or gallium maltolate for the treatment of ATRT.

Read more
2 May 2024 15:45

EARNINGS AND TRADING: Trident Royalties swings to profit

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
22 Feb 2024 14:02

IN BRIEF: IQ-AI shares sink on discounted placing fundraise

IQ-AI Ltd - Medical services firm and parent company of Wisconsin-based healthcare imaging software firm Imaging Biometrics LLC - Announces placing to raise GBP300,000 gross proceeds via the issue of 20.0 million new shares at a price of 1.5p each. The issue price represents a discount of 32% to the company's Wednesday closing price of 2.2p. The placing includes a broker option for existing shareholders for up to 6.7 million new shares, which would raise an additional GBP100,000. Admission of the new placing and broker option shares is expected to occur on or around March 1.

Read more
9 Feb 2024 13:38

IQ-AI subsidiary asked by FDA to resubmit and modify application

(Alliance News) - IQ-AI Ltd on Friday said its subsidiary Imaging Biometric LLC will modify and resubmit its application to the US Food & Drug Administration.

Read more
2 Feb 2024 08:56

IN BRIEF: IQ-AI celebrates USD100,000 grant for subsidiary

IQ-AI Ltd - St Helier, Jersey-based medical services firm - Says that Imaging Biometrics LLC, a wholly-owned subsidiary of IQ-AI, has been given a USD100,000 grant by the Musella Foundation For Brain Tumor Research & Information Inc. Explains that the grant will help to support the launch of an intermediate group expanded access programme, which is focused on giving brain tumour patients access to oral gallium maltolate, outside of an ongoing Phase One clinical trial at the Medical College of Wisconsin. The grant will be used to facilitate the expanded access programme, including writing and submitting the study protocol, patient screening and on-boarding.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.